Home A Different Class of ADT Control CV Risk Economic Burden of CVD Events Disease-Related Symptoms Delay Disease Progression Patient Satisfaction Support & Resources Dosing & Administration Firmagon Licence Prescribing Information

Firmagon degarelix. Think beyond the prostate

DEGARELIX FERRING licence and indication

How many of your patients could benefit from DEGARELIX FERRING's extended licence?

Learn More...

DEGARELIX FERRING extended licence

DEGARELIX FERRING is still the only GnRH antagonist approved before or after radiotherapy for patients with high-risk localised or locally advanced hormone-dependent prostate cancer.^1-3

Localised prostate cancer

Locally advanced PCa

Metastatic PCa

Low Risk

Intermediate Risk

High Risk

PSA <10 ng/mL

PSA 10-20 ng/mL

PSA >20 ng/mL

Any PSA

+ Gleason score <7

OR Gleason score =7

OR Gleason score >7

Any Gleason score

cT1-2a

OR T2b

OR T2c

T3-4 or N1

T3/4, N1, M1

DEGARELIX FERRING extended licence

DEGARELIX FERRING initial licence

Adapted from European Association of Urology Guidelines, 2022⁴

DEGARELIX FERRING is indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer, also in combination with radiotherapy and as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally hormone-dependent dependent prostate cancer.^1,2

DEGARELIX FERRING licence and indication

How many of your patients could benefit from DEGARELIX FERRING's extended licence?

DEGARELIX FERRING extended licence

▲ SECTION NAVIGATION ▲